MISSISSAUGA, ON, Jan. 6 /CNW/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, announced today that the Toronto Stock Exchange (“TSX”) has approved a warrant incentive program designed to encourage the early exercise of 20,012,494 warrants (the “November 2009 Warrants”), 3,901,898 warrants (the “June 2009 Warrants”) and 50,000,000 warrants (the “July 2009 Warrants”).
